Guidelines for Screening, Prophylaxis and Critical Information Prior to Initiating Anti-TNF-alpha Treatment

This clinical practice guideline is for cancer patients who are being considered for anti-TNF-alpha therapy. Treatment related infections are reviewed, including tuberculosis, human papilloma virus, hepatitis B and C, Varicella zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus and human immunodeficiency virus. The guideline discusses risk factors for developing infection, and provides recommendations on preventative measures such as vaccination for at-risk individuals.